The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase.
T-705 (Favipiravir) is a broad-spectrum antiviral molecule currently in late stage clinical development for the treatment of influenza virus infection. Although it is believed that T-705 potency is mediated by its ribofuranosyl triphosphate (T-705 RTP) metabolite that could be mutagenic, the exact m...
Guardado en:
Autores principales: | Zhinan Jin, Lucas K Smith, Vivek K Rajwanshi, Baek Kim, Jerome Deval |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b678aabdaccf4ba8b5c1a3f06d142108 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
por: Kritika Srinivasan, et al.
Publicado: (2021) -
Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
por: Hideki Tani, et al.
Publicado: (2016) -
Acta Nº705
por: Banco Central de Chile
Publicado: (2019) -
Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides
por: Bing Wang, et al.
Publicado: (2021) -
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
por: Ashleigh Shannon, et al.
Publicado: (2020)